HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034)
The overall HER2+ gastric cancer market is projected to grow, driven by increasing biomarker testing, better patient selection, and continued advancements in HER2-targeted ADCs, bispecific antibodies, and novel immune-based approaches. Additionally, the launch of therapies such as Zanidatamab (Jazz Pharmaceuticals), Rilvegostomig (AstraZeneca), Evorpacept (ALX Oncology), and others in the future is expected to bring a positive shift in the treatment landscape of HER2+ gastric cancer.
LAS VEGAS, June 9, 2025 /PRNewswire/ -- DelveInsight's HER2+ Gastric Cancer (including GEJ) Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of individual therapies, and current and forecasted HER2+ gastric cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the HER2+ Gastric Cancer Market Report
As per DelveInsight's analysis, the total market size of HER2+ gastric cancer (including GEJ) in the 7MM is approximately USD 700 million in 2024 and is projected to increase during the forecast period (2025–2034).
In 2024, among the current therapies for HER2+ gastric cancer, the largest revenue was generated by Trastuzumab ± Chemotherapy, i.e., USD 140 million in the United States.
The total number of incident cases of HER2+ gastric cancer in the 7MM accounted for approximately. 45,000 in 2024. These cases are expected to increase by 2034.
Leading HER2+ gastric cancer companies, such as AstraZeneca/Daiichi Sankyo, Merck, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, and others, are developing novel HER2+ Gastric cancer therapies that can be available in the HER2+ gastric cancer market in the coming years.
Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan), is the only approved therapy for the treatment of advanced or metastatic HER2+ gastric cancer for 2L therapy. The drug received accelerated approval in January 2021. Along with ENHERTU (trastuzumab deruxtecan), KEYTRUDA (pembrolizumab), and HERCEPTIN (trastuzumab) are approved for HER2+ gastric cancer for 1L therapy.
Daiichi Sankyo and AstraZeneca's ENHERTU is also expanding into the first-line treatment setting, which is expected to increase its patient share and, consequently, drive growth in the market size.
Some of the key HER2+ gastric cancer emerging therapies in the pipeline include ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others.
Data presented during the recent ASCO 2025 meeting showed that ENHERTU extended overall survival for more than 3 months in patients with advanced HER2-positive gastric or GEJA following progression on first-line therapy, based on the Phase III DESTINY-Gastric04 trial.
In February 2025, AstraZeneca anticipated a data readout from the Phase Ib/II (NCT04379596, DESTINY-Gastric03) trial, which was focused on treating metastatic or unresectable HER2+ gastric cancer, GEJ, and GEA, in 2026.
In February 2025, AstraZeneca expected the first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer or GEJ adenocarcinoma to begin in Q1 2025, with data anticipated to be available after 2026.
In the January 2025 presentation, Jazz Pharmaceuticals anticipated the potential approval and launch of zanidatamab as a first-line treatment for GEA in 2026. Additionally, the company is also looking forward to expanding its market strategy for zanidatamab in 2026.
In January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that the company's investigational CD47-blocker, evorpacept, produces a durable clinical response and exhibits a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric cancer or GEJ cancer.
Discover which therapies are expected to grab the HER2+ gastric cancer market share @ HER2+ Gastric Cancer Market Report
HER2+ Gastric Cancer Overview
Gastric cancer is the fifth most common type of cancer and the fourth leading cause of cancer-related deaths worldwide. HER2, also known as HER2/neu or ERBB2, is found in approximately 15–30% of gastric cancers, including those at the Gastroesophageal Junction (GEJ). It is located on chromosome 17q21 and is part of the EGFR family, which includes EGFR/HER1, HER3, and HER4. The ligand for the HER2 tyrosine kinase receptor remains unidentified. HER2 can form both homodimers and heterodimers with other EGFR family receptors, and overexpression of HER2 can result in ligand-independent activation. In gastric cancer, ERBB2 mutations are most commonly found in the CIN subtype, primarily consisting of missense mutations (74%), with smaller proportions of insertions (22%) and fusions (0.7%). HER2 expression is more frequently observed in the intestinal subtype (according to Lauren's classification), as well as in proximal gastric cancer, GEJ cancer, metastatic disease (particularly liver metastasis), and lymph node involvement.
HER2+ Gastric Cancer Epidemiology Segmentation
In the 7MM, in 2024, among all the HER2+ Gastric cancer indications, breast cancer accounted for the highest number of incident cases, while ovarian cancer occupied the bottom of the ladder. The HER2+ gastric cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Incident Cases of Gastric Cancer (including GEJ)
Gender-Specific Cases of Gastric Cancer (including GEJ)
Stage-Specific Cases of Gastric Cancer (including GEJ)
Total Incident Cases of HER2+ Gastric Cancer (including GEJ)
Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ)
HER2+ Gastric Cancer Treatment Market
HER2, which is overexpressed or amplified in 6–36% of gastric cancer patients, represents a key target in the development of novel treatment strategies for metastatic gastric cancer. While surgical resection remains the primary treatment and can cure patients with early-stage cancer, the survival rates for those with advanced resectable gastric or gastroesophageal junction cancers remain low, despite the introduction of new treatments like perioperative chemotherapy or adjuvant chemoradiation. For patients diagnosed with early-stage disease, gastrectomy is the standard treatment. However, survival rates for those with advanced resectable cancers are still poor, even with the addition of new therapies such as perioperative chemotherapy or adjuvant chemoradiation.
Treatment for HER2-positive gastric cancer depends on factors such as tumor size, location, and the patient's overall health. The humanized monoclonal antibody HERCEPTIN (trastuzumab) targets HER2, inhibiting the growth and survival of HER2-dependent tumors. Alongside HERCEPTIN, KEYTRUDA (Merck), one of the first therapies approved for gastric cancer, works by binding to the Programmed Cell Death-1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2, and reversing PD-1 pathway-mediated immune suppression, including the antitumor immune response. Most recent approvals for targeted therapies, such as ENHERTU (Daiichi Sankyo) and AIDIXI (Remegen Biosciences), are used in second- and third-line treatments for gastric cancer.
Learn more about the FDA-approved HER2+ gastric cancer therapies @ HER2+ Gastric Cancer Treatment Drugs
Key Emerging HER2+ Gastric Cancer and Companies
Various new therapies are in development with a focus on the mentioned limitations of the currently approved drugs. Some of the most prominent ones include Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN-002 (Enliven Therapeutics), ARX788 (Ambrx), Rilvegostomig (AstraZeneca), and others. These emerging drugs play a vital part in fulfilling the unmet need for the treatment approach of HER2+ gastric cancer.
Although the space is quite active and various trials are underway to treat patients with HER2+ gastric cancer, continuous efforts are further needed to develop novel drugs that would be more effective and less toxic.
ZIIHERA is a bispecific antibody targeting HER2, binding to two extracellular sites on the HER2 protein. In November 2024, the FDA granted accelerated approval for ZIIHERA for adult patients with previously treated, unresectable, or metastatic HER2+ (immunohistochemistry 3+) biliary tract cancer (BTC), identified through an FDA-approved test.
Jazz Pharmaceuticals expects to release top-line data in the second quarter of 2025 from the Phase III HERIZON-GEA-01 trial (NCT05152147), which is assessing zanidatamab combined with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive metastatic gastric and esophageal adenocarcinoma (GEA). According to the presentation, Jazz Pharmaceuticals aims to potentially approve and launch zanidatamab as a first-line treatment for gastric cancer in 2026. The company is also planning to expand its market strategy for zanidatamab in 2026.
HLX22 (AC101), a novel anti-HER2 monoclonal antibody developed by AbClon and further advanced by Henlius, is currently under investigation. In November 2024, Henlius Biotech announced that the first patient was dosed in the Phase III international multicenter clinical trial (HLX22-GC-301) for HLX22. In October 2024, Henlius received approval from Japan's PMDA for the Clinical Trial Notification (CTN) of a Phase III international multicenter study of HLX22, in combination with trastuzumab and chemotherapy, as a first-line treatment for HER2-positive advanced gastric cancer.
The other therapies in the HER2+ gastric cancer pipeline include
TUKYSA (tucatinib): Pfizer
BAY2927088: Bayer
AB-201 (GCC2003, HER2 CAR-NK): Artiva Biotherapeutics and GC Cell
A166 (Trastuzumab botidotin): KLUS Pharma
MRG002: Shanghai Miracogen
AIDIXI (disitamab vedotin): Pfizer
BAY2701439: Bayer
XMT-2056: Mersana Therapeutics and GSK
BL-M07D1: SystImmune
and others
The anticipated launch of these emerging therapies are poised to transform the HER2+ gastric cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HER2+ gastric cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about HER2+ gastric cancer drug clinical trials, visit @ HER2+ Gastric Cancer Drugs
HER2+ Gastric Cancer Market Dynamics
The HER2+ gastric cancer market dynamics are expected to change in the coming years. HER2-targeted therapies, such as HERCEPTIN, ENHERTU, and anti-PD1 therapy KEYTRUDA, offer more precise treatment by improving efficacy and minimizing side effects compared to traditional chemotherapy. Daiichi Sankyo and AstraZeneca's ENHERTU is expanding into the first-line treatment setting, which is expected to increase its patient share and drive market growth.
There is growing research interest in combining next-generation HER2 inhibitors or bispecific antibodies with Immune Checkpoint Inhibitors (ICIs), presenting significant opportunities to enhance treatment efficacy and improve patient survival. Additionally, the HER2+ gastric cancer market is projected to grow due to increased incidence rates, an aging population, and advancements in treatment methodologies, potentially leading to more investment in research and development.
Furthermore, potential therapies are being investigated for the treatment of HER2+ gastric cancer, and it is safe to predict that the treatment space will significantly impact the HER2+ gastric cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the HER2+ gastric cancer market in the 7MM.
However, several factors may impede the growth of the HER2+ gastric cancer market. HER2+ gastric cancer is an aggressive form of the disease with a significantly high mortality rate, poor survival rates, and a poor prognosis due to factors such as low screening rates, high rates of refractory/relapsed tumors, and the advanced age of patients. The complexity of tumor biology, including intratumoral heterogeneity, poses challenges to effective treatment strategies and limits the efficacy of current therapies. Additionally, HER2+ gastric cancer is prone to developing resistance to targeted therapies, highlighting the need for the continuous development of next-generation agents, which further increases R&D costs.
Moreover, HER2+ gastric cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the HER2+ gastric cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the HER2+ gastric cancer market growth.
HER2+ Gastric Cancer Report Metrics
Details
Study Period
2020–2034
HER2+ Gastric Cancer Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
HER2+ Gastric Cancer Market CAGR
13 %
HER2+ Gastric Cancer Market Size in 2024
USD 700 Million
Key HER2+ Gastric Cancer Companies
AstraZeneca/Daiichi SankyoJazz Pharmaceuticals, BeiGene, Zymeworks, Merck, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, and others
Key HER2+ Gastric Cancer Therapies
ENHERTU, KEYTRUDA, ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK) A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others
Scope of the HER2+ Gastric Cancer Market Report
HER2+ Gastric Cancer Therapeutic Assessment: HER2+ Gastric Cancer current marketed and emerging therapies
HER2+ Gastric Cancer Market Dynamics: Conjoint Analysis of Emerging HER2+ Gastric Cancer Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, HER2+ Gastric Cancer Market Access and Reimbursement
Discover more about HER2+ gastric cancer drugs in development @ HER2+ Gastric Cancer Clinical Trials
Table of Contents
1
Key Insights
2
Report Introduction
3
Executive Summary
4
Epidemiology and Market Methodology
5
HER2+ Gastric Cancer Market Overview at a Glance
5.1
Market Share (%) Distribution of HER2+ Gastric Cancer by Line of Therapies in 2020 in the 7MM
5.2
Market Share (%) Distribution of HER2+ Gastric Cancer by Line of Therapies in 2034 in the 7MM
5.3
Market Share (%) Distribution of HER2+ Gastric Cancer by Therapies in 2020 in the 7MM
5.4
Market Share (%) Distribution of HER2+ Gastric Cancer by Therapies in 2034 in the 7MM
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Molecular Subtypes of Gastric Cancer
7.3
HER2+ Gastric Cancer
7.4
Causes and Risk Factors Related to Gastric Cancer
7.5
Clinical Manifestations Related to Gastric Cancer
7.6
Diagnosis Related to Gastric Cancer
7.7
Staging of Gastric Cancer
7.8
Current Treatment Practices: Gastric Cancer
7.8.1
Treatment for HER2+ Gastric Cancer
8
Guidelines and Recommendations for HER2+ Gastric Cancer
8.1
PAN-ASIAN ADAPTED (PAGA) ESMO CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS, TREATMENT, AND FOLLOW-UP OF PATIENTS WITH GASTRIC CANCER (2024)
8.2
NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES FOR GASTRIC CANCER (2024)
8.3
NICE GUIDELINES FOR OESOPHAGO-GASTRIC CANCER (2023)
8.4
GASTRIC CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP (2022)
8.5
JAPANESE GASTRIC CANCER TREATMENT GUIDELINES (2021)
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationale: 7MM
9.3
Total Incident Cases of Gastric Cancer (including GEJ) in the 7MM
9.4
United States
9.4.1
Total Incident Cases of Gastric Cancer (including GEJ) in the United States
9.4.2
Gender-specific Cases of Gastric Cancer (including GEJ) in the United States
9.4.3
Stage-specific Cases of Gastric Cancer (including GEJ) in the United States
9.4.4
Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in the United States
9.4.5
Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) in the United States
9.5
EU4 and the UK
9.5.1
Total Incident Cases of Gastric Cancer (including GEJ) in EU4 and the UK
9.5.2
Gender-specific Cases of Gastric Cancer (including GEJ) in EU4 and the UK
9.5.3
Stage-specific Cases of Gastric Cancer (including GEJ) in EU4 and the UK
9.5.4
Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in EU4 and the UK
9.5.5
Total Incident Cases of Advanced HER2+ Gastric Cancer in EU4 and the UK
9.6
Japan
9.6.1
Total Incident Cases of Gastric Cancer (including GEJ) in Japan
9.6.2
Gender-specific Cases of Gastric Cancer (including GEJ) in Japan
9.6.3
Stage-specific Cases of Gastric Cancer (including GEJ) in Japan
9.6.4
Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in Japan
9.6.5
Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) in Japan
10
Patient Journey
11
Marketed Drug
11.1
Key Competitors
11.2
KEYTRUDA (pembrolizumab): Merck
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Development Activities
11.2.4
Clinical Development
11.2.5
Safety and Efficacy
11.3
ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo and AstraZeneca
11.3.1
Product Description
11.3.2
Regulatory Milestones
11.3.3
Other Development Activities
11.3.4
Clinical Development
11.3.5
Safety and Efficacy
12
Emerging Therapies
12.1
Key Cross Competition
12.2
ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.4
Safety and Efficacy
12.3
Rilvegostomig: AstraZeneca
12.3.1
Product Description
12.3.2
Clinical Development
12.4
HLX22 (AC101): Shanghai Henlius Biotech and AbClon
12.4.1
Product Description
12.4.2
Other Development Activity
12.4.3
Clinical Development
12.4.4
Safety and Efficacy
12.5
Evorpacept (ALX148): ALX Oncology
12.5.1
Product Description
12.5.2
Other Developmental Activities
12.5.3
Clinical Development
12.5.4
Safety and Efficacy
12.6
TUKYSA (tucatinib): Pfizer
12.6.1
Product Description
12.6.2
Other Development Activity
12.6.3
Clinical Development
12.6.4
Safety and Efficacy
13
HER2+ Gastric Cancer (including GEJ): 7MM Analysis
13.1
Key Findings
13.2
Market Outlook
13.3
Conjoint Analysis
13.4
Key Market Forecast Assumptions
13.4.1
Cost Assumptions and Rebates
13.4.2
Pricing Trends
13.4.3
Analogue Assessment
13.4.4
Launch Year and Therapy Uptake
13.5
Total Market Size of HER2+ Gastric Cancer (including GEJ) in the 7MM
13.6
United States Market Size
13.6.1
Total Market Size of HER2+ Gastric Cancer (including GEJ) in the United States
13.6.2
Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in the United States
13.7
EU4 and the UK Market Size
13.7.1
Total Market Size of HER2+ Gastric Cancer (including GEJ) in EU4 and the UK
13.7.2
Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in EU4 and the UK
13.8
Japan Market Size
13.8.1
Total Market Size of HER2+ Gastric Cancer (including GEJ) in Japan
13.8.2
Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in Japan
14
Unmet Needs
15
SWOT Analysis
16
KOL Views
17
Market Access and Reimbursement
17.1
United States
17.1.1
Centre for Medicare and Medicaid Services (CMS)
17.2
EU4 and the UK
17.2.1
Germany
17.2.2
France
17.2.3
Italy
17.2.4
Spain
17.2.5
United Kingdom
17.3
Japan
17.3.1
MHLW
17.4
Market Access and Reimbursement of HER2+ Gastric Cancer (including GEJ)
18
Appendix
18.1
Bibliography
18.2
Report Methodology
19
DelveInsight Capabilities
20
Disclaimer
Related Reports
HER2+ Gastric Cancer Pipeline
HER2+ Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others.
HER2+ Gastric Cancer Epidemiology
HER2+ Gastric Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends.
Gastric Cancer Market
Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including Hanmi Pharmaceuticals, Merck, Minneamrita Therapeutics, Taiho Pharmaceuticals, Bayer, among others.
Gastric Cancer Pipeline
Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastric cancer companies, including EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/her2-gastric-cancer-including-gej-market-to-increase-at-a-remarkable-growth-rate-of-13-during-the-study-period-20202034--delveinsight-302476182.html
SOURCE DelveInsight Business Research, LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
11 minutes ago
- Business Upturn
L&T secures major orders worth up to 10,000 crore for Power Transmission & Distribution business
Larsen & Toubro (L&T) today announced that its Power Transmission & Distribution (PT&D) business has secured major orders, classified in the ₹5,000 – ₹10,000 crore range, for grid infrastructure projects in both domestic and international markets. In India, the business has won an order to construct 765kV and 400kV transmission lines associated with the integration of a Renewable Energy Zone in Andhra Pradesh. This project is aligned with India's ongoing energy transition efforts and will play a key role in enhancing green power evacuation infrastructure. In the Middle East, PT&D has received turnkey orders to establish 220kV and 132kV Gas Insulated Substations (GIS). These contracts have been awarded by prominent transmission asset owners and operators in the respective countries. The new orders reinforce PT&D's capabilities in executing complex power transmission projects and mark a strategic step toward supporting global sustainable energy goals. In the meantime, Larsen & Toubro shares opened at ₹3,704 and hit a low of ₹3,667.20 during early trade. The stock remains close to its 52-week high of ₹3,963.50, showing strong medium-term momentum. Its 52-week low stands at ₹2,965.30. About L&T: Larsen & Toubro is a USD 30 billion Indian multinational engaged in EPC projects, hi-tech manufacturing, and services, with operations across multiple geographies. The company has maintained leadership across key sectors for over eight decades through a strong customer-centric approach and commitment to quality. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Insider
an hour ago
- Business Insider
Jazz Pharmaceuticals presents late-breaking phase 4 data showcasing Xywav
Jazz Pharmaceuticals (JAZZ) 'announced late-breaking Phase 4 data evaluating treatment benefits of Xywav oral solution in people with narcolepsy. These results are two of Jazz's four late-breaking abstracts presented today as oral presentations at SLEEP 2025. The four late-breaking abstracts, selected for their scientific quality and innovation, comprise all industry-sponsored late-breaking oral presentations selected by the Associated Professional Sleep Societies. Xywav is the only low-sodium oxybate approved by the U.S. Food and Drug Administration for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy and for adults with idiopathic hypersomnia. The Xywav label recommends a nightly dose of 6-9 grams per night.' Confident Investing Starts Here:
Business Insider
an hour ago
- Business Insider
‘Don't Bet the Bank,' Says Investor About Ripple (XRP)
Ripple (XRP-USD) has been one of the biggest beneficiaries of the shifting political and regulatory landscape following Trump's November election victory. The outcome was widely seen as a win for the broader cryptocurrency market, fueled by expectations that the new administration would adopt a more favorable stance toward digital assets. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter So far, those expectations have largely been met. The administration includes several prominent crypto advocates, and Trump's executive order to establish a Strategic Bitcoin Reserve further signaled that crypto has entered the policy mainstream. A major development came with leadership changes at the U.S. Securities and Exchange Commission (SEC). Crypto critic Gary Gensler stepped down, replaced by Paul Atkins – a known proponent of digital assets – bringing promises of lighter-touch regulation and clearer guidance. That shift proved especially pivotal for Ripple Labs. The company had been locked in a years-long legal battle with the SEC over allegations that XRP was sold as an unregistered security. With the new leadership in place, many hoped the case would be dropped, and earlier this year, that's exactly what happened. So, with that catalyst in tow, it's no wonder XRP went on a huge run in the wake of Trump's election win, and is now still trading 342% above pre-election levels, even after a 32% pullback from January's high. Investor Bram Berkowitz notes that removing this 'big overhang' enables Ripple to concentrate on its core mission: streamlining cross-border payments. XRP is well-suited for this role, offering faster and cheaper transactions than traditional systems. Ripple has also launched a stablecoin, RLUSD, to strengthen XRP's utility as a bridge between currencies. On top of that, its recent $1.25 billion acquisition of prime broker Hidden Road signals a push toward greater institutional adoption. And with several firms now seeking approval for XRP spot ETFs, additional demand may soon follow. But the question is whether all that merits an investment in XRP. According to Berkowitz, that's a tougher call than it seems. Cryptocurrencies are notoriously hard to value – there's no cash flow to analyze, and prices are often driven more by hype and headlines than fundamentals. But XRP isn't just another speculative token. It boasts a real-world use case, capable of handling 1,500 transactions per second, which positions it as a strong contender for powering fast, cost-effective cross-border payments. On the other hand, there are also competitors who can process transactions at a fast pace. That said, XRP benefits from being part of Ripple's expanding ecosystem, which now includes a stablecoin, a major prime broker, and established banking partners – potentially positioning it as the go-to token for institutional payments. 'For this reason,' Berkowitz sums up, 'I think XRP is worth a small, speculative investment, but I wouldn't invest too heavily in the token just yet because it's still too volatile.' (To watch Berkowitz's track record, click here) To find good ideas for crypto stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
